Tnfrsf12a Mouse Gene Knockout Kit (CRISPR)

CAT#: KN317976LP

Tnfrsf12a - mouse gene knockout kit via CRISPR, HDR mediated




 HDR-mediated knockout kit validation

  See Other Versions

CNY 12,260.00


货期*
6周

规格
    • 1 kit

Product images

经常一起买 (3)
pCAS-Scramble, pCas-Guide vector with a scrambled sequence as a negative control (10 µg)
    • 10 ug

CNY 3,710.00


Tnfrsf12a Antibody - N-terminal region
    • 50 ug

CNY 4,628.00


Tnfrsf12a (Myc-DDK-tagged) - Mouse tumor necrosis factor receptor superfamily, member 12a (Tnfrsf12a), transcript variant 1
    • 10 ug

CNY 1,200.00
CNY 3,705.00

Specifications

Product Data
Format 2 gRNA vectors, 1 Luciferase-Puro donor, 1 scramble control
Donor DNA Luciferase-Puro
Symbol Tnfrsf12a
Locus ID 27279
Kit Components

KN317976G1, Tnfrsf12a gRNA vector 1 in pCas-Guide CRISPR vector

KN317976G2, Tnfrsf12a gRNA vector 2 in pCas-Guide CRISPR vector

KN317976LP-D, donor DNA containing left and right homologous arms and Luciferase-Puro functional cassette.

GE100003, scramble sequence in pCas-Guide vector

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process.
Reference Data
RefSeq NM_001161746, NM_013749
Synonyms AI255180; C87282; Fn14; HPIP; TWEAK-R; TweakR
Summary Receptor for TNFSF12/TWEAK (By similarity). Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins.[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...